| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 342.3 | 278.6 |
| Profit before tax | 80.4 | 44.6 |
| Net income | 53.5 | 71.8 |
| EPS (diluted, $ a share) | $0.31 | $0.42 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -25.4% |
|---|---|
| Revenue, year on year | +22.8% |
| Operating margin | 21.0% |
10-Q filed with the SEC, NASDAQ: ACAD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Acadia Pharmaceuticals Inc: key numbers
- Share price
- $18.67Close, Nov 16
- Market cap
- $3.23B
- Shares outstanding
- 172.83MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Acadia Pharmaceuticals Inc
All →Acadia Pharmaceuticals Earnings Call: Key Takeaways
Acadia delivered strong Q3 results with 22% revenue growth, raised DAYBUE guidance, and optimized its Phase 3 ADP program despite a Phase 2 primary endpoint miss, supported by a $976 million cash position.
- Call
- Nov 4, 2026, 4:30 PM ET
Acadia Pharmaceuticals Financial Results
Acadia Pharmaceuticals reported Q3 2026 total revenues of $342 million, a 22% increase year-over-year, driven by strong sales of DAYBUE and NUPLAZID. The company raised its 2026 net sales guidance for DAYBUE to $505–$520 million and highlighted upcoming Phase 2 readouts for its pipeline candidates in 2027.
- Term
- Q3 2026
“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID. In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany. NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach.”
Catherine Owen Adams, Chief Executive Officer of Acadia
Acadia Pharmaceuticals EVP, CFO Mark C. Schneyer Sells $69.3K of Stock
Mark C. Schneyer, EVP, CFO, sold 3,321 shares of Acadia Pharmaceuticals Inc at $20.88 a share, worth $69.3K in total on Oct 30, 2026. Shares held after the trade: 71,322 (-4.4%).
- Value
- $69.3K
- Shares
- 3,321
- Price
- $20.88
- Role
- EVP, CFO
- Holding change
- -4.4%
- Trade date
- Oct 30, 2026
Acadia Pharmaceuticals Leadership Change
Elizabeth H.Z. Thompson, Ph.D., has stepped down from her role as Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals effective October 23, 2026. Dr. Thompson will transition to a consulting role through December 31, 2026, while the company continues its search for a permanent replacement.
- Term
- through Dec 2026
Acadia Pharmaceuticals Clinical Trial Data
Acadia Pharmaceuticals announced Phase 3 enabling topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer’s disease psychosis (ADP). While the 60 mg dose narrowly missed the primary endpoint (p=0.0603), it showed nominal significance on a key secondary endpoint and a favorable safety profile, leading the company to continue its Phase 3 program with the 60 mg dose.
- Earnings call
- Sep 24, 2026, 8:00 AM ET
Acadia Pharmaceuticals Court & Legal Update
The U.S. District Court for the Southern District of California has granted preliminary approval for a settlement of a stockholder derivative action against Acadia Pharmaceuticals and certain of its officers and directors. The settlement resolves claims related to the company's drug pimavanserin (NUPLAZID) and includes the implementation of corporate governance reforms and the payment of plaintiff attorney fees. A final settlement hearing is scheduled for January 13, 2027.
- Counterparty
- Kanner et al.